<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01346371</url>
  </required_header>
  <id_info>
    <org_study_id>MAC-01-11</org_study_id>
    <nct_id>NCT01346371</nct_id>
  </id_info>
  <brief_title>The Effect of BEPREVE 1.5% on Tear Film Osmolarity and Tear Film Lipid Layer</brief_title>
  <official_title>The Effect of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% on Tear Film Osmolarity and Tear Film Lipid Layer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Minnesota Eye Consultants, P.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Minnesota Eye Consultants, P.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effect of Bepreve® with an artificial-tear eye
      drop on the quality of your tears.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, randomized, parallel group, placebo-controlled study to evaluate the
      effect of BEPREVE compared to a placebo eye drop on the measurement of tear film osmolarity
      and tear film lipid layer in patients with allergic conjunctivitis.

      Subjects will be screened for this study on day one of dosing with the test article. Subjects
      who sign the informed consent form and who meet all inclusion/exclusion criteria will be
      eligible for participation in this study. They will be assigned sequentially, according to a
      computer generated randomization list, in a ratio of 1:1 to receive either BEPREVE™
      (bepotastine besilate ophthalmic solution) 1.5% or REFRESH TEARS® Lubricant Eye Drops (1:1).
      Subjects will instill one drop of test article either BEPREVE™ or REFRESH TEARS® into the
      study eyes twice daily for a maximum of 60 days. Subjects will be seen for evaluation on Days
      0, 28±3, and 56±3 following randomization.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tear Osmolarity</measure>
    <time_frame>56 days after initial screening visit</time_frame>
    <description>The TearLab Osmolarity System will be used to assess tear film osmolarity, measured in mOsms/L.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Allergic Conjunctivitis</condition>
  <arm_group>
    <arm_group_label>Refresh Tears® eye drops</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Must add drops twice a day every day during trial enrollment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bepreve® 1.5% solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Must add drops twice a day every day while enrolled in trial.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Refresh Tears 0.5% Lubricant Eye Drops</intervention_name>
    <arm_group_label>Bepreve® 1.5% solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bepreve 1.5% Ophthalmic Solution</intervention_name>
    <arm_group_label>Refresh Tears® eye drops</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Are male or female at least 18 years of age who are diagnosed with allergic
             conjunctivitis.

          2. Have documented positive skin prick puncture test to at least one (1) seasonal
             allergen (e.g., grasses, trees, weeds, or other allergens) within two (2) years of
             Visit 1.

          3. Agree not to have any other ocular drops in study eyes within 2 days prior to the
             initiation of dosing with the test article or throughout the duration of the study.

          4. Have a Best Corrected Visual Acuity of 20/200 or better in either eye.

          5. Are willing/able to follow instructions from the study investigator and his/her staff.

          6. Be willing/able to return for all required study visits, to follow instructions from
             the study investigator and his/her staff.

          7. Are able to self-administer test article (or have a caregiver available to instill all
             doses of test article).

          8. Have signed informed consent approved by Institutional Review Board or Independent
             Ethics Committee.

        Exclusion Criteria:

          1. Have known hypersensitivity to either BEPREVE™ or REFRESH TEARS® or to any component
             of the test article (including &quot;procedural&quot; medications such as anesthetic and/or
             fluorescein drops, dilating drops, etc.).

          2. Have active corneal pathology noted in the study eye at the screening visit. Active
             corneal pathology is defined as corneal pathology that is non-stable, or greater than
             mild, or will compromise assessment of the safety or efficacy of treatment.

          3. Have used topical, ocular, inhaled or systemic steroids within 14 days prior to
             screening.

          4. Have a history of abuse of alcohol/drugs within six months prior to the screening
             visit.

          5. Are pregnant or nursing/lactating.

          6. Have participated in any other study of an investigational drug or device within 30
             days prior to randomization.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmad M Fahmy, O.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Minnesota Eye Consultants</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Minnesota Eye Consultants, P.A.</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mneye.com</url>
    <description>Minnesota Eye Consultants</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>April 29, 2011</study_first_submitted>
  <study_first_submitted_qc>May 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2011</study_first_posted>
  <results_first_submitted>September 19, 2012</results_first_submitted>
  <results_first_submitted_qc>March 19, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 31, 2020</results_first_posted>
  <last_update_submitted>March 19, 2020</last_update_submitted>
  <last_update_submitted_qc>March 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Allergic</keyword>
  <keyword>conjunctivitis</keyword>
  <keyword>Allergic conjunctivitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Lubricant Eye Drops</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment began Aug 15, 2011 and concluded June 11, 2012. There are a variety of sources we recruited our subjects from which is outlined below:
Email. PI referrals, employee, and subject referrals. Flyers posted around college campuses. Website clinicaltrial.gov.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Refresh Tears® Eye Drops</title>
          <description>Must add drops twice a day every day during trial enrollment.</description>
        </group>
        <group group_id="P2">
          <title>Bepreve® 1.5% Solution</title>
          <description>Must add drops twice a day every day while enrolled in trial.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Refresh Tears® Eye Drops</title>
          <description>Must add drops twice a day every day during trial enrollment.</description>
        </group>
        <group group_id="B2">
          <title>Bepreve® 1.5% Solution</title>
          <description>Must add drops twice a day every day while enrolled in trial.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40" spread="13"/>
                    <measurement group_id="B2" value="35" spread="12"/>
                    <measurement group_id="B3" value="38" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Tear Osmolarity</title>
        <description>The TearLab Osmolarity System will be used to assess tear film osmolarity, measured in mOsms/L.</description>
        <time_frame>56 days after initial screening visit</time_frame>
        <population>Analysis per protocol as ITT and LOCF for all subject eyes.</population>
        <group_list>
          <group group_id="O1">
            <title>Refresh Tears® Eye Drops</title>
            <description>Must add drops twice a day every day during trial enrollment.</description>
          </group>
          <group group_id="O2">
            <title>Bepreve® 1.5% Solution</title>
            <description>Must add drops twice a day every day while enrolled in trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Tear Osmolarity</title>
          <description>The TearLab Osmolarity System will be used to assess tear film osmolarity, measured in mOsms/L.</description>
          <population>Analysis per protocol as ITT and LOCF for all subject eyes.</population>
          <units>mOsM/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="303" spread="3.13"/>
                    <measurement group_id="O2" value="303" spread="2.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Refresh Tears® Eye Drops</title>
          <description>Must add drops twice a day every day during trial enrollment.</description>
        </group>
        <group group_id="E2">
          <title>Bepreve® 1.5% Solution</title>
          <description>Must add drops twice a day every day while enrolled in trial.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular Irritation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Ocular Burning</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Ocular itching</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="20"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>General eye discomfort</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Stomach problems</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Cold like symptoms</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="20"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Bad Taste in mouth</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint/muscle pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ahmad Fahmy, OD</name_or_title>
      <organization>Minnesota Eye Consultants, P.A.</organization>
      <phone>612-813-3665</phone>
      <email>amfahmy@mneye.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

